Review
Biochemistry & Molecular Biology
Marek Ziobro, Aleksandra Grela-Wojewoda
Summary: Patients with HR-positive, HER2-negative breast cancer constitute the majority of breast cancer population. CDK4/6 inhibitors have significantly improved the outcomes as first-line treatment for these patients. However, access to CDK4/6 inhibitors in Poland is limited to patients participating in the drug program, which may pose challenges for both patients and clinicians.
Editorial Material
Oncology
Niamh C. Cunningham, Nicholas C. Turner
Summary: CDK4/6 inhibitors have shown consistent efficacy in the treatment of metastatic breast cancer, but recent adjuvant trials for early stage breast cancer have produced conflicting results, highlighting the need for further research on their clinical utility and future trial design.
Article
Oncology
Neelima Denduluri, Mark R. Somerfield, Mariana Chavez-MacGregor, Amy H. Comander, Zoneddy Dayao, Andrea Eisen, Rachel A. Freedman, Ragisha Gopalakrishnan, Stephanie L. Graff, Michael J. Hassett, Tari A. King, Gary H. Lyman, Gillian Rice Maupin, Raquel Nunes, Cheryl L. Perkins, Melinda L. Telli, Maureen E. Trudeau, Antonio C. Wolff, Sharon H. Giordano
Summary: The study recommends offering 14 cycles of adjuvant T-DM1 to patients with HER2-positive breast cancer with pathologic invasive residual disease after standard preoperative chemotherapy and HER2-targeted therapy, based on the results of the KATHERINE trial.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Inga Bekes, Jens Huober
Summary: Seventy percent of breast cancer subtypes are hormone receptor-positive, and adjuvant endocrine therapy is crucial for these patients. Extending adjuvant endocrine therapy beyond 5 years has been shown to reduce the risk of late recurrence, but the optimal duration is still debated. Newer data suggest only marginal benefits beyond 7 to 10 years, and longer duration may result in more side effects. Therefore, it is important to select patients who qualify for extended therapy based on genomic tests and risk assessment.
Article
Oncology
Olivia Pagani, Barbara A. Walley, Gini F. Fleming, Marco Colleoni, Istvan Lang, Henry L. Gomez, Carlo Tondini, Harold J. Burstein, Matthew P. Goetz, Eva M. Ciruelos, Vered Stearns, Herve R. Bonnefoi, Silvana Martino, Charles E. Geyer, Claudio Chini, Fabio Puglisi, Simon Spazzapan, Thomas Ruhstaller, Eric P. Winer, Barbara Ruepp, Sherene Loi, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan, Prudence A. Francis
Summary: The combined analysis of SOFT-TEXT compared the outcomes of 4,690 premenopausal women with ER/PgR+ early breast cancer randomly assigned to exemestane + OFS or tamoxifen + OFS. Exemestane + OFS showed significant improvement in DFS and DRFI, but not overall survival, compared to tamoxifen + OFS. This study provides guidance for selecting patients who may benefit from exemestane over tamoxifen in the setting of OFS.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frederique Penault-Llorca, Aleix Prat
Summary: Breast cancer multigene signatures (BCMS) have changed the management of early-stage breast cancer (eBC) by providing prognostic information and helping select patients for adjuvant chemotherapy. However, there is limited knowledge on the current usage and perceived utility of BCMS in clinical practice. A two-round Delphi survey involving 133 breast cancer experts from 11 European countries revealed that BCMS are widely used to assess risk of recurrence and select patients for adjuvant chemotherapy, but consensus is lacking regarding their utility in selecting specific chemotherapy types. There are also discrepancies between recommended usage and actual usage, with some profiles lacking supporting evidence. The study suggests the need for physician education initiatives to ensure proper use and interpretation of BCMS, ultimately improving management of eBC patients.
Article
Oncology
Sharon H. Giordano, Rachel A. Freedman, Mark R. Somerfield
Summary: ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations in response to new and practice-changing data, aiming to disseminate updated recommendations in a timely manner to inform health practitioners and the public on the best available cancer care options.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Michael Gnant, Florian Fitzal, Gabriel Rinnerthaler, Guenther G. Steger, Sigrun Greil-Ressler, Marija Balic, Dietmar Heck, Raimund Jakesz, Josef Thaler, Daniel Egle, Diether Manfreda, Vesna Bjelic-Radisic, Ursula Wieder, Christian F. Singer, Elisabeth Melbinger-Zeinitzer, Ferdinand Haslbauer, Paul Sevelda, Harald Trapl, Viktor Wette, Kerstin Wimmer, Simon P. Gampenrieder, Rupert Bartsch, Stephanie Kacerovsky-Strobl, Christoph Suppan, Christine Brunner, Christine Deutschmann, Lidija Soelkner, Christian Fesl, Richard Greil
Summary: This study showed that extending hormone therapy by 5 years in postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Oncology
Leopoldo Sitia, Marta Sevieri, Lorena Signati, Arianna Bonizzi, Arianna Chesi, Francesco Mainini, Fabio Corsi, Serena Mazzucchelli
Summary: Breast cancer is a major cause of death in females worldwide, and nanotechnologies have shown significant potential in improving both therapeutic and diagnostic aspects, especially in HER-2-positive breast cancer. This review provides an update on the most promising nanoparticle-based approaches developed in the last decade for HER-2-positive breast cancer therapy and diagnosis.
Review
Biochemistry & Molecular Biology
Domenico Iacopetta, Jessica Ceramella, Noemi Baldino, Maria Stefania Sinicropi, Alessia Catalano
Summary: Breast cancer is one of the most common and deadly cancers among women worldwide. Surgery, radiotherapy, and chemotherapy are the main treatments, but chemotherapy often fails due to side effects and damage to healthy tissues. New studies are needed to find new therapies and strategies for aggressive and metastatic breast cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Ilana Schlam, Paolo Tarantino, Stefania Morganti, Filipa Lynce, Dario Trapani, Erica L. Mayer, Ana C. Garrido-Castro, Ada Waks, Sara M. Tolaney
Summary: Breast cancer is a common and deadly disease in the US, and recent advancements in treatment for early-stage breast cancer include the use of immune checkpoint inhibitors for triple-negative breast cancer and CDK4/6 inhibitors for hormone receptor-positive disease. Additionally, adjuvant olaparib has shown significant improvement in outcomes for patients with BRCA1/2 mutations and high-risk HER2-negative breast cancer.
Review
Pharmacology & Pharmacy
Chao Dong, Jiao Wu, Yin Chen, Jianyun Nie, Ceshi Chen
Summary: Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression in breast cancer patients. Current research is focusing on developing drugs targeting this pathway to overcome acquired resistance to standard therapies.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Julia Foldi, Anastasia Tsagianni, Max Salganik, Catherine A. Schnabel, Adam Brufsky, G. J. van Londen, Lajos Pusztai, Tara Sanft
Summary: Extending adjuvant endocrine therapy beyond the standard 5 years can protect against late breast cancer recurrences. This study evaluated persistence to extended therapy in women who had Breast Cancer Index testing, and found high rates of persistence in patients with predicted high likelihood of benefit.
Article
Oncology
M. A. A. Ragusi, B. H. M. van der Velden, M. C. van Maaren, E. van der Wall, C. H. van Gils, R. M. Pijnappel, K. G. A. Gilhuijs, S. G. Elias
Summary: By estimating the expected breast cancer-specific survival (BCSS) of adjuvant systemic therapy (AST) using PREDICT, this study aims to quantify the number of patients treated with AST without benefit and provide estimates of overtreatment. The results suggest that many treated patients do not benefit from AST, especially in the case of endocrine therapy.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Pharmacology & Pharmacy
Zhe Wang, Beibei Guo, Shujing Yue, Songsong Zhao, Fenghua Meng, Zhiyuan Zhong
Summary: A HER-2 directed nano-delivery system efficiently suppresses orthotopic epithelial ovarian cancer and metastasis, and significantly prolongs the survival time of mice.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Article
Surgery
Angela Hill, Franklin Olumba, William Chapman
Summary: Transplantation for HCC is a complex topic, requiring considerations of multiple factors. Balancing tumor size with post-transplant outcome is still an ongoing challenge. Tumor downstaging and the use of new technologies have increased the number of HCC transplants, and these advances can also be applied to other liver tumors.
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Olanrewaju A. Eletta, Guergana G. Panayotova, Keri E. Lunsford
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Brianna Ruch, Kayla Kumm, Sandra Arias, Nitin N. Katariya, Amit K. Mathur
Summary: DCD liver transplantation is an underutilized method that can increase access to liver transplantation. With proper donor and recipient selection, matching, surgical technique, and perioperative management, these transplants can achieve similar patient and graft survival rates as DBD liver transplantation. The main limitations in the further growth of DCD liver transplantation are driven by risk aversion, and the current experience is mainly concentrated in large centers. With the advancement of regional and machine perfusion techniques, the definition of a viable DCD liver allograft may be redefined, encouraging wider usage and acceptance.
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Lauren Matevish, Madhukar S. Patel, Parsia A. Vagefi
Summary: Downstaging has been shown to be feasible within UNOS-DS criteria, with successful long-term outcomes. Interventional liver-directed therapies have been the standard, but systemic therapies are becoming more effective. Immunotherapy holds promise in downstaging, but further trials are needed to assess feasibility and safety. Individual expertise will continue to guide treatment until more data is available.
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Hassan Aziz, Paramita Nayak, David C. Mulligan
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Catherine G. Pratt, Jenna N. Whitrock, Shimul A. Shah, Zhi Ven Fong
Summary: hCCA is a biologically aggressive disease and surgical resection is the only curative treatment. Factors such as patient's physical condition, tumor involvement, residual liver volume, and assessment of metastatic disease heavily influence the feasibility of surgical resection. A multidisciplinary, holistic, and individualized approach is critical for accurately determining resectability and optimizing clinical outcomes for patients with hCCA.
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Sara-Catherine Whitney Zingg, Kristina Lemon
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Christopher J. Sonnenday
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Alban Longchamp, Tsukasa Nakamura, Korkut Uygun, James F. Markmann
SURGICAL CLINICS OF NORTH AMERICA
(2024)